IDEAYA BIOSCIENCES AND SERVIER ANNOUNCE FIRST PATIENT DOSED IN OPTIMUM-11 GLOBAL PHASE 3 REGISTRATIONAL TRIAL OF DAROVASERTIB AND CRIZOTINIB AS ADJUVANT THERAPY FOR SUBJECTS WITH UVEAL MELANOMA

Reuters · 2d ago

Please log in to view news